Delivering Novel Therapies for RAS/MAPK Pathway Driven Cancers

With nearly a third of all cancers associated with alterations in the RAS/MAPK pathway, these highly aggressive cancers often recur, with patients rarely experiencing optimal outcomes. We are bold in our commitment to inhibit this pathway, discover novel options, and ultimately redefine hope to address this urgent need.  

Our clinical program is powered by a robust portfolio of ongoing trials and strategic collaborations, centered on novel small molecule inhibitors targeting the critical RAS/MAPK signaling pathway in cancer. This is the driving force fueling innovative edge of our pipeline through the purposeful use of  combination therapies.